Volume 19, Number 12—December 2013
Research
Guillain-Barré Syndrome Surveillance during National Influenza Vaccination Campaign, New York, USA, 2009
Gregory P. Giambrone1
, Shelley M. Zansky, Millicent Eidson, Pamela G. Duncan, Louise-Anne McNutt, and Guthrie S. Birkhead
, Shelley M. Zansky, Millicent Eidson, Pamela G. Duncan, Louise-Anne McNutt, and Guthrie S. Birkhead
Table 3
Vaccination status of patients with confirmed or probable GBS, New York State Department of Health GBS surveillance system, 2009–2010*-
| Reporting source | Total confirmed/probable GBS case-patientss | A(H1N1)pdm09 monovalent vaccine status |
|
|---|---|---|---|
| Received, no. (%) | Did not receive, no. (%) | ||
| Clinical Network† and SPARCS‡ | 140 | 19 (14) | 121 (86) |
| SPARCS | 130 | 19 (15) | 111 (85) |
| Clinical Network | 91 | 13 (14) | 78 (86) |
| SPARCS-only¶ | 49 | 6 (12) | 43 (88) |
*GBS, Guillain-Barré syndrome; SPARCS, Statewide Planning and Research Cooperative System.
†Network of >2,494 reporting clinical neurologists.
‡SPARCS refers to all suspected cases identified through hospital discharge data (some of these cases might have been identified by the Clinical Network as well).
¶Cases missed by the Clinical Network and identified only through SPARCS.
1Current affiliation: Weill Cornell Medical College, New York, New York, USA.
Page created: November 19, 2013
Page updated: November 19, 2013
Page reviewed: November 19, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.